Eflornithine (DFMO) for Ewing sarcoma and osteosarcoma
Part of Cancer clinical trials.
This trial tests a drug called eflornithine (DFMO) for people with Ewing sarcoma or osteosarcoma that has come back or spread. The goal is to see if DFMO can help control the cancer after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years old or younger (or under 30 for some osteosarcoma cases).
- You have either Ewing sarcoma or osteosarcoma that has come back or spread.
- You are able to have surgery or radiation to remove the main tumor after some chemo.
- Your kidneys, liver, heart, and blood counts are working well enough.
- You are not currently taking other cancer treatments or experimental drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (eflornithine and AMXT 1501) for children and young adults with certain types of cancer that have relapsed or not responded to standard treatment, or for a specific brain tumor (DIPG) at diagnosis. The goal is to see if this drug pair is safe and effective.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and fluzoparib) for people with Ewing sarcoma that has spread or come back after first treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests new drugs for young people with Ewing sarcoma or similar sarcomas that have come back or not responded to standard treatment. The goal is to see if these drugs can shrink or control the cancer.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This study tests a combination of two drugs, cabozantinib and ifosfamide, for sarcomas that have come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a personalized radiation therapy that adjusts the dose based on your tumor. It aims to improve treatment for Ewing sarcoma while limiting side effects.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.